BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dupert (Fulzerasib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dupert (Fulzerasib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07492342-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07492342)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Th
 erapy for Resectable KRAS G12C-Mutant NSCLC\nEstimated primary completion:
  31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulze
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492342
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936644-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT06936644)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Multicenter\, Single-arm Phase II Study to Evaluate the Efficacy an
 d Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) i
 n First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cance
 r Patients With KRAS G12C Mutation\nEstimated primary completion: 30 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulzerasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0693664
 4
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959589-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT06959589)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2.\nStudy: The Efficacy and Safety 
 of IBI351\, Cetuximab β Combined With FOLFIRI as First-line /IBI351\, Cet
 uximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic 
 Colorectal Cancer\nEstimated primary completion: 31 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fulzerasib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06959589
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198841-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07198841)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Ca
 ncer With KRAS G12C Mutation\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fulzerasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07198841
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463677-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07463677)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally
  Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulzerasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07463677
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581912-2487@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07581912)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2.\nStudy: Neoadjuvant Treatment of
  Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Color
 ectal Cancer With or Without Resectable Metastases\nEstimated primary comp
 letion: December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/fulzerasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07581912
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
